Advertisement

Der Radiologe

, Volume 58, Issue 12, pp 1060–1066 | Cite as

Marklagerveränderungen nach Chemotherapie und Bestrahlung

  • A. Simgen
Leitthema
  • 105 Downloads

Zusammenfassung

Heutzutage gehören Chemotherapie und Radiotherapie zu den leitliniengerechten Therapiekonzepten zur Behandlung von malignen Tumoren des Zentralnervensystems. Neurologische Symptome oder bildmorphologische Veränderungen des Marklagers können bei beiden Behandlungsmethoden anhand des zeitlichen Auftretens in akut, subakut und chronisch eingeteilt werden. Sowohl die Symptome als auch die bildmorphologischen Marklagerveränderungen im akuten und subakuten Stadium sind in den meisten Fällen vollständig reversibel. Chronische Leukenzephalopathien können zu ausgeprägten neurologischen Einschränkungen führen und die Lebensqualität von Krebspatienten zusätzlich beeinträchtigen.

Schlüsselwörter

Gehirn Weiße Substanz Nervenfasern Magnetresonanztomographie Leukenzephalopathie 

White matter alterations after chemotherapy and radiation

Abstract

Nowadays chemotherapy and radiotherapy are fundamental therapy concepts in the guidelines of malignant tumors of the central nervous system. Both therapy concepts can cause neurological symptoms or white matter alterations can occur, which can be classified into acute, subacute and chronic. Both symptoms and white matter alterations during acute and subacute phases are in most cases completely reversible, whereas chronic white matter alterations can lead to severe neurological limitations and further impair the quality of life of cancer patients.

Keywords

Brain White matter Nerve fibers Magnetic resonance imaging Leukoencephalopathies 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A. Simgen gibt an, dass kein Interessenkonflikt besteht.

Alle beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zuständigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) durchgeführt. Von allen beteiligten Patienten liegt eine Einverständniserklärung vor.

Literatur

  1. 1.
    Bleyer WA (1981) Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65(Suppl 1):89–98PubMedGoogle Scholar
  2. 2.
    Bücheler E, Lackner K‑J, Thelen M (2005) Einführung in die Radiologie, 11. Aufl. Georg Thieme Verlag, StuttgartGoogle Scholar
  3. 3.
    Cross NE, Glantz MJ (2003) Neurologic complications of radiation therapy. Neurol Clin 21:249–277CrossRefPubMedGoogle Scholar
  4. 4.
    DeAngelis LM, Delattre JY, Posner JB (1989) Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789–796CrossRefPubMedGoogle Scholar
  5. 5.
    Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122CrossRefPubMedGoogle Scholar
  6. 6.
    Fisher MJ, Khademian ZP, Simon EM, Zimmerman RA, Bilaniuk LT (2005) Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. Ajnr Am J Neuroradiol 26:1686–1689PubMedGoogle Scholar
  7. 7.
    Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, Schmidt-Wolf I, Schlegel U (2003) Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563–568.  https://doi.org/10.1001/archneur.60.4.563 CrossRefPubMedGoogle Scholar
  8. 8.
    Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180–188.  https://doi.org/10.1097/01.nrl.0000080951.78533.c4 CrossRefPubMedGoogle Scholar
  9. 9.
    Goldsby RE, Liu Q, Nathan PC, Bowers DC, Yeaton-Massey A, Raber SH, Hill D, Armstrong GT, Yasui Y, Zeltzer L, Robison LL, Packer RJ (2010) Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 28:324–331.  https://doi.org/10.1200/JCO.2009.22.5060 CrossRefPubMedGoogle Scholar
  10. 10.
    Gonzalez J, Kumar AJ, Conrad CA, Levin VA (2007) Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67:323–326.  https://doi.org/10.1016/j.ijrobp.2006.10.010 CrossRefPubMedGoogle Scholar
  11. 11.
    Honkaniemi J, Kähärä V, Dastidar P, Latvala M, Hietaharju A, Salonen T, Keskinen L, Ollikainen J, Vähämäki L, Kellokumpu-Lehtinen P, Frey H (2000) Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology 42:895–899CrossRefPubMedGoogle Scholar
  12. 12.
    How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE (2016) Chemotherapy-associated posterior reversible Encephalopathy syndrome: a case report and review of the literature. Neurologist 21:112–117.  https://doi.org/10.1097/NRL.0000000000000105 CrossRefPubMedGoogle Scholar
  13. 13.
    Kim JH, Brown SL, Jenrow KA, Ryu S (2008) Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J Neurooncol 87:279–286.  https://doi.org/10.1007/s11060-008-9520-x CrossRefPubMedGoogle Scholar
  14. 14.
    Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:20–27.  https://doi.org/10.1016/j.ijrobp.2009.02.091 CrossRefGoogle Scholar
  15. 15.
    Linn J, Wiesmann M, Brückmann H (2011) Atlas Klinische Neuroradiologie des Gehirns. Springer, Berlin, HeidelbergCrossRefGoogle Scholar
  16. 16.
    Lövblad K, Kelkar P, Ozdoba C, Ramelli G, Remonda L, Schroth G (1998) Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr Radiol 28:86–91.  https://doi.org/10.1007/s002470050299 CrossRefPubMedGoogle Scholar
  17. 17.
    Maytal J, Grossman R, Yusuf FH, Shende AC, Karayalycin G, Lanzkowsky P, Schaul N, Eviatar L (1995) Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 36:831–836CrossRefPubMedGoogle Scholar
  18. 18.
    Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309.  https://doi.org/10.1200/JCO.2005.04.6086 CrossRefPubMedGoogle Scholar
  19. 19.
    Nieder C, Ataman F, Price RE, Ang KK (1999) Biological prevention and/or therapy possibility of radiation myelopathy. A discussion of recent perspectives. Strahlenther Onkol 175:437–443CrossRefPubMedGoogle Scholar
  20. 20.
    Ochs J, Mulhern R, Fairclough D, Parvey L, Whitaker J, Ch’ien L, Mauer A, Simone J (1991) Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9:145–151.  https://doi.org/10.1200/JCO.1991.9.1.145 CrossRefPubMedGoogle Scholar
  21. 21.
    Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, Yoshida M, Kaneda M, Suzuki Y, Miyasaka K (2003) MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45:493–497.  https://doi.org/10.1007/s00234-003-0983-3 CrossRefPubMedGoogle Scholar
  22. 22.
    Posner JB (1995) Neurologic complications of cancer. Oxford University Press, USAGoogle Scholar
  23. 23.
    Primavera A, Audenino D, Cocito L (2002) Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 29:180–183CrossRefPubMedGoogle Scholar
  24. 24.
    Reddick WE, Glass JO, Helton KJ, Langston JW, Li C‑S, Pui C‑H (2005) A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. Ajnr Am J Neuroradiol 26:2371–2377PubMedPubMedCentralGoogle Scholar
  25. 25.
    Reddy AT, Witek K (2003) Neurologic complications of chemotherapy for children with cancer. Curr Neurol Neurosci Rep 3:137–142CrossRefPubMedGoogle Scholar
  26. 26.
    Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51:159–165CrossRefPubMedGoogle Scholar
  27. 27.
    Schlegel U, Pels H, Oehring R, Blümcke I (1999) Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol 43:277–286CrossRefPubMedGoogle Scholar
  28. 28.
    Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, Steinmetz A, Stein J, Goshen Y, Yaniv I (2000) Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 15:573–580.  https://doi.org/10.1177/088307380001500902 CrossRefPubMedGoogle Scholar
  29. 29.
    Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I (2002) Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J 4:1050–1053PubMedGoogle Scholar
  30. 30.
    Steeghs N, de Jongh FE, Sillevis Smitt PAE, van den Bent MJ (2003) Cisplatin-induced encephalopathy and seizures. Anticancer Drugs 14:443–446.  https://doi.org/10.1097/01.cad.0000078733.65608.38 CrossRefPubMedGoogle Scholar
  31. 31.
    Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4:529–536CrossRefPubMedGoogle Scholar
  32. 32.
    Supprian T, Kessler H, Retz W, Rösler M, Grunwald I, Reith W, Falkai P (2003) White matter alterations in neurodegenerative and vascular dementia. Radiologe 43:543–551.  https://doi.org/10.1007/s00117-003-0916-5 CrossRefPubMedGoogle Scholar
  33. 33.
    Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L (2001) Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 24:145–148CrossRefPubMedGoogle Scholar
  34. 34.
    Verstappen CCP, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563CrossRefPubMedGoogle Scholar
  35. 35.
    Vezmar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92–104.  https://doi.org/10.1159/000069773 CrossRefPubMedGoogle Scholar
  36. 36.
    Vogl TJ, Reith W, Rummeny EJ (2016) Diagnostic and interventional radiology. Springer, Berlin, HeidelbergCrossRefGoogle Scholar
  37. 37.
    Wenz F, Steinvorth S, Lohr F, Fruehauf S, Wildermuth S, van Kampen M, Wannenmacher M (2000) Prospective evaluation of delayed central nervous system (CNS) toxicity of hyperfractionated total body irradiation (TBI). Int J Radiat Oncol Biol Phys 48:1497–1501CrossRefPubMedGoogle Scholar
  38. 38.
    Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46.  https://doi.org/10.1111/j.1529-8027.2008.00156.x CrossRefPubMedGoogle Scholar
  39. 39.
    Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4:273–284.  https://doi.org/10.1124/mi.4.5.7 CrossRefPubMedGoogle Scholar
  40. 40.
    Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, Schmidt-Wolf IGH (2002) Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 13:629–631CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Diagnostische und Interventionelle NeuroradiologieUniversitätsklinikum des SaarlandesHomburg/SaarDeutschland

Personalised recommendations